9 September 2025
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Notification of dealings by a director/PDMR
Aptamer Group plc (AIM: APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, today announces that Dr Adam Hargreaves, Non-Executive Chairman, on 8 September 2025 purchased 5,000,000 ordinary shares of £0.001 each ("Ordinary Shares") in the Company at a price of 1 pence per Ordinary Share, through Pathcelerate Limited.
Following this transaction, Dr Adam Hargreaves total beneficial interest in the Company is 175,379,305 Ordinary Shares, representing approximately 6.50% of the Company's issued share capital.
The following disclosures are made in accordance with the requirements of the UK Market Abuse Regulation and provide detail in relation to the purchase of ordinary shares by directors and other PDMRs in the Company.
NOTIFICATIONS AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
||||
|
a) |
Name |
Dr Adam Hargreaves (Pathcelerate Limited) |
|||
|
2 |
Reason for the notification |
||||
|
a) |
Position/status |
Non-Executive Chairman |
|||
|
b) |
Initial notification /Amendment |
Initial notification |
|||
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name |
Aptamer Group plc |
|||
|
b) |
LEI |
213800Y4XGH3WJNBE686 |
|||
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument |
Ordinary shares of £0.001 each |
|||
|
Identification code |
GB00BNRRP542 |
||||
|
b) |
Nature of the transaction |
Purchase of shares |
|||
|
c) |
Price(s) and volume(s) |
Price 1p Volume 5,000,000 |
|||
|
d) |
Aggregated information |
||||
|
- Aggregated volume |
5,000,000 |
||||
|
- Price |
1p |
||||
|
e) |
Date of the transaction |
8 September 2025 |
|||
|
f) |
Place of the transaction |
London Stock Exchange |
|||
- Ends -
For further information, please contact:
|
Aptamer Group plc Dr Arron Tolley, Chief Executive Officer |
+44 (0) 1904 217 404 |
|
SPARK Advisory Partners Limited - Nominated Adviser Andrew Emmott / Jade Bayat |
+44 (0) 20 3368 3550 |
|
Turner Pope Investments (TPI) Limited - Broker James Pope / Andrew Thacker |
+44 (0) 20 3657 0050 |
|
Northstar Communications Limited - Investor Relations Sarah Hollins |
+44 (0) 113 730 3896 |
About Aptamer Group
Aptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.
Aptamer operates a fee-for-service business in the US$210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.
Founded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.
To register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/